Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes. Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users. Read More
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
NEW YORK - November 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
RADNOR, PA - November 21, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
LOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK - November 20, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services. For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system available.
RADNOR, PA - November 19, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DexCom, Inc. (NASDAQ:DXCM), Synopsys, Inc. (NASDAQ:SNPS), CarMax, Inc. (NYSE:KMX), and Fiserv, Inc. (NYSE:FI). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8, 2024 and September 17, 2025, inclusive..
NEW YORK - November 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider.
RADNOR, PA - November 18, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) ( NASDAQ: DXCM ) on behalf of those who purchased or otherwise acquired DexCom securities between January 8, 2024, and September 17, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is December 26, 2025.
NEW YORK - November 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation.
